Literature DB >> 11508581

Influence of longterm therapy with methotrexate and low dose corticosteroids on type 1 and type 2 cytokine production in CD4+ and CD8+ T lymphocytes of patients with rheumatoid arthritis.

A J Schuerwegh1, J F van Offel, C H Bridts, W J Stevens, L S De Clerck.   

Abstract

OBJECTIVE: Rheumatoid arthritis (RA) is a chronic inflammatory disease with predominance of type I cytokine [interleukin 2 (IL-2), interferon-gamma (IFN-gamma)] production. In this prospective study, we evaluated the influence of longterm therapy with methotrexate (MTX) in combination with low dose corticosteroids on the type 1/type 2 cytokine balance in RA.
METHODS: Peripheral blood mononuclear cells were isolated from 10 controls and 20 patients with RA before therapy and after 12 mo of therapy with MTX in combination with low dose corticosteroids. Using flow cytometry, the intracellular production of IL-2, IFN-gamma, and IL-4 was measured in CD4+ and CD8+ T lymphocytes.
RESULTS: Compared with healthy controls, patients with RA before therapy showed an increased percentage of IL-2 positive CD4+ and CD8+ T cells (p = 0.002, p = 0.01, respectively). An increased percentage of IFN-gamma positive CD8+ T cells was found (p = 0.0006) compared with the control group. After 12 months of therapy, a significantly decreased percentage of IL-2 positive CD4+ T cells and IFN-gamma positive CD4+ and CD8+ T lymphocytes was observed (p = 0.0003, p = 0.0007, p = 0.001). The percentage of IL-4/IFN-gamma positive CD4+ and CD8+ T cells was significantly higher after 12 months of therapy (p = 0.01, p = 0.02). There was a positive correlation between the percentage of IFN-gamma positive CD4+ T cells and disease activity variables (Ritchie Index and number of swollen joints) in RA patients before therapy (r = 0.6, p = 0.04 and r = 0.4, p = 0.05).
CONCLUSION: Longterm therapy with MTX in combination with low dose corticosteroids for RA influenced the predominance of type 1 cytokines toward normalization of the cytokine balance in both CD4+ and CD8+ T lymphocytes.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11508581

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  6 in total

1.  Differential effects of leflunomide and methotrexate on cytokine production in rheumatoid arthritis.

Authors:  M C Kraan; T J M Smeets; M J van Loon; F C Breedveld; B A C Dijkmans; P P Tak
Journal:  Ann Rheum Dis       Date:  2004-04-28       Impact factor: 19.103

Review 2.  A molecule solves psoriasis? Systemic therapies for psoriasis inducing interleukin 4 and Th2 responses.

Authors:  Kamran Ghoreschi; Ulrich Mrowietz; Martin Röcken
Journal:  J Mol Med (Berl)       Date:  2003-07-18       Impact factor: 4.599

3.  Circulating lymphocyte subsets linked to intracellular cytokine profiles in normal humans.

Authors:  M Matsui; S Araya; H-Y Wang; N Onai; K Matsushima; T Saida
Journal:  Clin Exp Immunol       Date:  2003-11       Impact factor: 4.330

4.  Restored and Enhanced Memory T Cell Immunity in Rheumatoid Arthritis After TNFα Blocker Treatment.

Authors:  Asma Khanniche; Ling Zhou; Bin Jiang; Jing Song; Yanhua Jin; Jian Yin; Shujun Wang; Ping Ji; Hao Shen; Ying Wang; Huji Xu
Journal:  Front Immunol       Date:  2019-04-24       Impact factor: 7.561

5.  Multiparameter phospho-flow analysis of lymphocytes in early rheumatoid arthritis: implications for diagnosis and monitoring drug therapy.

Authors:  Carole L Galligan; Janet C Siebert; Katherine A Siminovitch; Edward C Keystone; Vivian Bykerk; Omar D Perez; Eleanor N Fish
Journal:  PLoS One       Date:  2009-08-20       Impact factor: 3.240

6.  Comparison of CD4 Counts with Mycophenolate Mofetil versus Methotrexate from the First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial.

Authors:  Christina L Kong; Nicole K Kelly; Miel Sundararajan; S R Rathinam; John A Gonzales; Radhika Thundikandy; Rajesh Vedhanayaki; Anuradha Kanakath; Bala Murugan; Thuy Doan; Debra Goldstein; Hassan A Al-Dhibi; Nisha R Acharya
Journal:  Ocul Immunol Inflamm       Date:  2020-08-11       Impact factor: 3.070

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.